Fly News Breaks for August 1, 2019
Aug 1, 2019 | 08:01 EDT
Vertex Pharmaceuticals reported "solid" Q2 results that set up for an "exciting 2020 story," Jefferies analyst Michael Yee tells investors in a post-earnings research note. He believes the earnings update on cystic fibrosis, the eventual triple launch, and all the new "2020 pipeline optionality" should drive "attractive upside to the stock" following the recent pullback. The analyst sees potential upside of 25%-50% and keeps a Buy rating on Vertex with a $210 price target.
News For VRTX From the Last 2 Days
There are no results for your query VRTX